Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

Ahn, MJ; Mendoza, MJL; Pavlakis, N; Kato, T; Soo, RA; Kim, DW; Liam, CK; Hsia, TC; Lee, CK; Reungwetwattana, T; Geater, S; Chan, OSH; Prasongsook, N; Solomon, BJ; Nguyen, TTH; Kozuki, T; Yang, JCH; Wu, YL; Mok, TSK; Tan, DS; Yatabe, Y

Author(s): Ahn, MJ; Mendoza, MJL; Pavlakis, N; Kato, T; Soo, RA; Kim, DW; Liam, CK; Hsia, TC; Lee, CK; Reungwetwattana, T; Geater, S; Chan, OSH; Prasongsook, N; Solomon, BJ; Nguyen, TTH; Kozuki, T; Yang, JCH; Wu, YL; Mok, TSK; Tan, DS; Yatabe, Y;
Details: Publication Year 2022-12,Volume 23,Issue #8,Page 670-685
Journal Title: Clinical Lung Cancer
Publication Type: Guideline
Abstract: Non-small cell lung cancer (NSCLC) is a heterogeneous disease, with many oncogenic driver mutations, including de novo mutations in the Mesenchymal Epithelial Transition (MET) gene (specifically in Exon 14 [ex14]), that lead to tumourigenesis. Acquired alterations in the MET gene, specifically MET amplification is also associated with the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in patients with EGFR-mutant NSCLC. Although MET has become an actionable biomarker with the availability of MET-specific inhibitors in selected countries, there is differential accessibility to diagnostic platforms and targeted therapies across countries in Asia-Pacific (APAC). The Asian Thoracic Oncology Research Group (ATORG), an interdisciplinary group of experts from Australia, Hong Kong, Japan, Korea, Mainland China, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam, discussed testing for MET alterations and considerations for using MET-specific inhibitors at a consensus meeting in January 2022, and in subsequent offline consultation. Consensus recommendations are provided by the ATORG group to address the unmet need for standardised approaches to diagnosing MET alterations in NSCLC and for using these therapies. MET inhibitors may be considered for first-line or second or subsequent lines of treatment for patients with advanced and metastatic NSCLC harbouring MET ex14 skipping mutations; MET ex14 testing is preferred within multi-gene panels for detecting targetable driver mutations in NSCLC. For patients with EGFR-mutant NSCLC and MET amplification leading to EGFR TKI resistance, enrolment in combination trials of EGFR TKIs and MET inhibitors is encouraged.
Keywords: Humans; *Carcinoma, Non-Small-Cell Lung/diagnosis/drug therapy/genetics; Drug Resistance, Neoplasm/genetics; ErbB Receptors/genetics; *Lung Neoplasms/diagnosis/drug therapy/genetics; Mutation; Protein Kinase Inhibitors/therapeutic use/pharmacology; Proto-Oncogene Proteins c-met; *Epithelial-Mesenchymal Transition; Asia-Pacific; Lung cancer; MET amplification in EGFR TKI resistance; MET exon 14 mutation; MET inhibitors
Department(s): Medical Oncology
PubMed ID: 36151006
Publisher's Version: https://doi.org/10.1016/j.cllc.2022.07.012
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-09-25 04:53:37

Last Modified: 2024-09-25 05:00:19